CIK 0001640266
- Accelerated filer
- Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-01-21 | Turenne Andre President & CEO | Sale | −10,705 | $13.36 | $143K | 85,545 |
| 2019-06-13 | PAUL STEVEN M Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | KARSEN PERRY A Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | PIERCE GLENN Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | GERAGHTY JAMES A Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | LEVIN MARK J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | Higgins Michael J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | Hyman Steven Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-06-13 | DIXON WENDY L Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-05-20 | Khwaja Omar | Grant or award | +30,000 | 30,000 | ||
| 2019-05-20 | Khwaja Omar | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 | ||
| 2019-04-01 | Hesslein Robert W. Senior VP & General Counsel | Grant or award | +28,125 | 28,125 | ||
| 2019-04-01 | Hesslein Robert W. Senior VP & General Counsel | Grant or award · Stock Option (Right to Buy) | +168,750 | 168,750 | ||
| 2019-03-12 | NEUROCRINE BIOSCIENCES INC 10% owner | Purchase | +4,179,728 | $11.96 | $50.0M | 4,179,728 |
| 2019-01-11 | Turenne Andre President & CEO | Grant or award | +96,250 | 96,250 | ||
| 2019-01-11 | Turenne Andre President & CEO | Grant or award · Stock Option (Right to Buy) | +192,500 | 192,500 | ||
| 2019-01-11 | Sah Dinah Ph.D. Chief Scientific Officer | Grant or award | +25,000 | 163,688 | ||
| 2019-01-11 | Sah Dinah Ph.D. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2019-01-11 | Ottmer Matthew P. Chief Operating Officer | Grant or award | +30,000 | 30,000 | ||
| 2019-01-11 | Ottmer Matthew P. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 |
Page 14 of 19 · 368 trades